Several MKIs inhibitors, that have been investigated in the treatment of RET-rearranged NSCLC, are approved for the treatment of thyroid cancers (i.e., vandetanib, cabozantinib, lenvatinib and sorafenib) or are approved for other indications (i.e., ponatinib, alectinib and sunitinib). Here, RET is linked to thyroid gland carcinoma.